-
Loading metrics
Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
- George Fountzilas,
- Vassiliki Kotoula,
- Dimitrios Pectasides,
- George Kouvatseas,
- Eleni Timotheadou,
- Mattheos Bobos,
- Xanthipi Mavropoulou,
- Christos Papadimitriou,
- Eleni Vrettou,
- Georgia Raptou
x
- Published: July 23, 2013
- https://doi.org/10.1371/journal.pone.0069256